Researchers discovered that a natural plant compound called DIM (found in cruciferous vegetables like broccoli and cabbage) may help treat fatty liver disease by blocking a harmful chemical pathway in the body. In mouse studies, DIM reduced fat buildup in the liver and decreased inflammation. The compound works by stopping the production of a molecule called TMAO, which appears to make fatty liver disease worse. While these results are promising, the research was only done in mice, so scientists need to test whether it works the same way in humans before recommending it as a treatment.
The Quick Take
- What they studied: Whether a natural plant compound (DIM) can reduce fatty liver disease by blocking a specific harmful chemical pathway in the body
- Who participated: Laboratory mice that were fed a special diet to develop fatty liver disease similar to what happens in humans
- Key finding: DIM significantly reduced fat accumulation in the liver and decreased inflammation markers in mice with fatty liver disease. When researchers added back the harmful chemical (TMAO), DIM’s benefits disappeared, showing that blocking this chemical is how DIM works.
- What it means for you: This research suggests DIM might eventually become a treatment for fatty liver disease, but it’s still in early stages. The compound is already found naturally in vegetables like broccoli, cauliflower, and Brussels sprouts. However, don’t expect supplements to be a cure yet—human studies are needed first.
The Research Details
Scientists used laboratory mice to study how fatty liver disease develops and how DIM might help treat it. They created fatty liver disease in mice by feeding them a special diet low in choline (a nutrient) combined with high fat. They then examined the mice’s livers at the genetic level to understand which genes and proteins were active during the disease.
The researchers tested DIM in two ways: first by adding it to cells in a dish to see if it reduced fat buildup, and second by giving it to sick mice to see if it improved their condition. They also did experiments where they added back the harmful chemical (TMAO) to see if it would undo DIM’s benefits. This helped them understand exactly how DIM works.
They measured several markers of liver health, including liver enzymes (ALT and AST) that leak into the blood when the liver is damaged, and the amount of fat stored in liver cells.
This research approach is important because it identifies a specific chemical pathway that drives fatty liver disease. By understanding the exact mechanism, scientists can develop targeted treatments rather than just treating symptoms. The fact that blocking this pathway with DIM reversed the disease in mice suggests it could be a real therapeutic target for humans.
This is original research published in a peer-reviewed scientific journal, which means other experts reviewed it before publication. The study used both cell-based experiments and living animal models, which strengthens the findings. However, the research is preliminary—it was only done in mice, not humans. The sample size of mice is not specified in the abstract, which is a limitation. Results in mice don’t always translate to humans, so human clinical trials would be needed to confirm these findings.
What the Results Show
The main discovery was that a protein called FMO3 is overactive in the livers of mice with fatty liver disease. This overactivity leads to production of a harmful molecule called TMAO. When researchers gave DIM to sick mice, it significantly reduced the amount of fat in their livers and decreased markers of liver damage (ALT and AST levels).
The researchers proved that DIM works by blocking the FMO3-TMAO pathway because when they added TMAO back to the mice, DIM’s protective effects disappeared. This shows that stopping TMAO production is the key mechanism by which DIM helps. In cell experiments, DIM also reduced fat accumulation and inflammatory chemicals that damage the liver.
The results suggest that DIM addresses both of the main problems in fatty liver disease: excessive fat storage and inflammation. This dual action makes it potentially more effective than treatments that only target one problem.
The study found that the FMO3-TMAO pathway is a previously underappreciated driver of fatty liver disease. While scientists knew this pathway was important for heart disease, they didn’t realize it played such a big role in liver disease. The research also showed that DIM’s benefits were specifically tied to blocking this pathway, not from other general anti-inflammatory effects.
Previous research had identified the FMO3-TMAO pathway as important for atherosclerosis (hardening of arteries) and heart disease. This study extends that knowledge by showing the same pathway is critical in fatty liver disease. The findings fit with existing research showing that TMAO levels are elevated in people with metabolic diseases. DIM is already known to have anti-inflammatory properties, but this is one of the first studies showing it works specifically by blocking the FMO3-TMAO axis.
The most significant limitation is that all experiments were conducted in mice, not humans. Mouse studies don’t always translate to human biology. The abstract doesn’t specify how many mice were used, making it difficult to assess statistical power. The study used a specific type of diet-induced fatty liver disease model, which may not represent all forms of the disease in humans. The research was conducted in laboratory conditions, not in real-world settings where diet, exercise, and other factors vary. Long-term effects of DIM treatment were not evaluated. The study doesn’t address whether DIM would work in people who already have advanced liver disease.
The Bottom Line
Based on this research, DIM cannot yet be recommended as a treatment for fatty liver disease in humans (moderate confidence in the mechanism, low confidence in human application). Eating vegetables naturally containing DIM (broccoli, cabbage, cauliflower, Brussels sprouts) as part of a healthy diet is reasonable and has other health benefits. DIM supplements should not be used to treat fatty liver disease without consulting a doctor, as human safety and effectiveness data are lacking. People with fatty liver disease should focus on proven interventions: weight loss, reducing sugar and refined carbohydrates, limiting alcohol, and increasing physical activity.
This research is most relevant to people with non-alcoholic fatty liver disease (NAFLD) and researchers developing new treatments. It may also interest people at risk for fatty liver disease due to obesity, diabetes, or metabolic syndrome. Healthcare providers treating liver disease should be aware of this emerging research direction. People should NOT use this as a reason to start taking DIM supplements without medical guidance. This research is not yet applicable to clinical practice.
If DIM proves effective in human trials (which haven’t started yet), it would likely take 5-10 years before it could become an approved treatment. Even then, it would probably work best as part of a comprehensive approach including lifestyle changes. Don’t expect immediate results—fatty liver disease develops over years, and reversing it takes time.
Want to Apply This Research?
- Track weekly servings of cruciferous vegetables (broccoli, cauliflower, cabbage, Brussels sprouts) and monitor liver health markers (ALT/AST levels from blood tests) every 3-6 months if you have fatty liver disease. Set a goal of 3-4 servings per week.
- Add one cruciferous vegetable to your diet each week. Start by including broccoli or cauliflower in one meal daily. Log your vegetable intake in the app and track how you feel. Combine this with other proven lifestyle changes like reducing sugar intake and increasing physical activity.
- Create a long-term tracking system that monitors: (1) weekly vegetable consumption, (2) weight trends, (3) energy levels, and (4) scheduled liver function blood tests every 6 months. Use the app to set reminders for blood work and to log dietary changes. Track correlation between dietary improvements and liver health markers over 6-12 months.
This research was conducted in mice and has not been tested in humans. DIM should not be used to treat or prevent fatty liver disease without consulting your healthcare provider. If you have fatty liver disease or suspect you might, speak with your doctor about proven treatments including weight loss, dietary changes, and exercise. Do not replace medical treatment with supplements based on this preliminary research. Always inform your healthcare provider about any supplements you’re considering, as they may interact with medications or existing health conditions.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.